This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
To evaluate intravenous immunoglobulin (IVIG) for patients with myasthenia gravis crisis compared with plasma exchange (PLEX).
Interventions
Intravenous immunoglobulin of 400mg/kg for five days and plasma exchange with an exchange frequency of 5.5.
Location/setting
USA/secondary care.
Methods

Analytical approach:
A decision tree model was developed to compare the two treatment options over the short term. The main focus of the comparison was resources incurred as a consequence of treatment choice. The authors did not state the perspective of their study.
Effectiveness data:
Clinical data came from published trials. The key clinical endpoint was prevalence of side effects during plasma exchange or intravenous immunoglobulin. Side-effects included death, bleeding, catheter occlusion, infection, nausea, hypotension and DVT (deep vein thrombosis). Data were derived from two prospective myasthenia treatment studies.
Monetary benefit and utility valuations:
None.
Measure of benefit:
No summary benefit was used. The authors stated that there was no evidence to establish clear clinical dominance of one over the other. An assumption of equal benefit was made.
Cost data:
Costs include those associated with professional services, hospitalisation (included intensive unit care), medicines, intravenous immunoglobulin, plasma exchange, albumin, laboratory tests and catheter costs (included catheter placement and catheter removal). Costs of treating side-effects were considered. Most cost data were collected from the Billing Office at the University of Rochester, supplemented where necessary from the literature. In-patient use of resources was based on a clinical study conducted at four major USA tertiary centres. All costs were reported in United
